Nakasya, Akio http://orcid.org/0000-0001-5244-5392
Hagiwara, Yuya
Ikoma, Tatsuki
Kurioka, Yusuke
Matsumoto, Toshihiko
Yamamoto, Yoshiyuki
Tsuduki, Takao
Kajiwara, Takeshi
Moriwaki, Toshikazu
Nishina, Tomohiro
Yamashita, Natsumi
Hyodo, Ichinosuke
Article History
Received: 15 October 2021
Accepted: 3 January 2022
First Online: 28 January 2022
Declarations
:
: Akio Nakasya has no conflict of interest. Takeshi Kajiwara received honoraria for lectures from Chugai Pharmaceutical, Taiho Pharmaceutical, Bristol-Myers Squibb, Merck Biopharmaceutical, and Ono Pharmaceutical. Toshikazu Moriwaki received honoraria for lectures from Taiho Pharmaceutical, Bristol-Myers Squibb, and Eli Lilly. Tomohiro Nishina received honoraria for lectures from Chugai Pharmaceutical, Taiho Pharmaceutical, Ono Pharmaceutical, Takeda Pharmaceutical, and Daiichi-Sankyo Pharmaceutical. Ichinosuke Hyodo received payment for consulting services from Asahi-Kasei Pharmaceutical and honoraria for lectures from Chugai Pharmaceutical, Takeda Pharmaceutical, and Yakult-Honsha, and payment as a Safety Monitoring board member from Chugai Pharmaceutical, Taiho Pharmaceutical, Ono Pharmaceutical, Daiichi-Sankyo Pharmaceutical, and Merck Serano Pharmaceutical. Yuya Hagiwara, Tatsuki Ikoma, Yusuke Kurioka, Toshihiko Matsumoto, Yoshiyuki Yamamoto, Takao Tsuduki, and Natsumi Yamashita have no conflict of interest.
: The study protocol was approved by the ethics committees of all participating institutions (approval number: 2020–65 at Shikoku Cancer Center, approval number: R03-022 at University of Tsukuba, approval number: 2020–46 at Himeji Red Cross Hospital, approval number: zn210121 at Kobe City Medical Center General Hospital). The requirement for informed consent was waived because the study design was retrospective. Opt-out opportunities were provided on each institution’s website. This research was conducted in accordance with the tenets of the Declaration of Helsinki.